Sanofi (NASDAQ:SNY) Given Consensus Recommendation of “Hold” by Brokerages

Shares of Sanofi (NASDAQ:SNY) have been assigned a consensus recommendation of “Hold” from the thirteen brokerages that are covering the company, MarketBeat.com reports. Eight investment analysts have rated the stock with a hold recommendation and five have assigned a buy recommendation to the company. The average 12 month price objective among analysts that have issued a report on the stock in the last year is $62.6667.

SNY has been the subject of a number of research analyst reports. Wall Street Zen upgraded Sanofi from a “buy” rating to a “strong-buy” rating in a research report on Saturday, January 31st. Citigroup began coverage on Sanofi in a report on Tuesday, January 27th. They issued a “neutral” rating for the company. Barclays cut Sanofi from an “overweight” rating to an “equal weight” rating in a research note on Tuesday, January 6th. Guggenheim cut shares of Sanofi from a “buy” rating to a “neutral” rating in a research report on Tuesday, December 9th. Finally, JPMorgan Chase & Co. reissued a “neutral” rating on shares of Sanofi in a report on Monday, December 8th.

Institutional Investors Weigh In On Sanofi

Large investors have recently modified their holdings of the stock. Lloyd Advisory Services LLC. acquired a new stake in shares of Sanofi during the fourth quarter worth $187,000. Keudell Morrison Wealth Management purchased a new stake in Sanofi during the fourth quarter valued at about $596,000. Axxcess Wealth Management LLC boosted its holdings in shares of Sanofi by 4.0% in the fourth quarter. Axxcess Wealth Management LLC now owns 10,818 shares of the company’s stock worth $524,000 after buying an additional 415 shares during the period. Pzena Investment Management LLC boosted its holdings in shares of Sanofi by 76.3% in the fourth quarter. Pzena Investment Management LLC now owns 11,749 shares of the company’s stock worth $569,000 after buying an additional 5,083 shares during the period. Finally, Newport Trust Company LLC purchased a new position in shares of Sanofi in the fourth quarter worth approximately $37,421,000. 14.03% of the stock is owned by institutional investors.

Sanofi Stock Performance

Shares of SNY opened at $47.83 on Monday. The firm has a market capitalization of $116.66 billion, a PE ratio of 13.29, a P/E/G ratio of 1.24 and a beta of 0.45. The company has a quick ratio of 0.29, a current ratio of 1.09 and a debt-to-equity ratio of 0.20. The firm has a 50-day moving average price of $47.91 and a 200 day moving average price of $48.65. Sanofi has a 52-week low of $44.62 and a 52-week high of $60.12.

About Sanofi

Sanofi (NASDAQ:SNY) is a multinational pharmaceutical company headquartered in France that researches, develops, manufactures and markets prescription medicines, vaccines and consumer healthcare products. The company operates across multiple therapeutic areas, including immunology, rare diseases, oncology, cardiovascular and metabolic diseases, and vaccines through its Sanofi Pasteur division. Sanofi sells products to hospitals, clinics, governments and retail pharmacies, with a broad global footprint and significant presence in Europe, North America and emerging markets.

Key commercial offerings include specialty biologics and established small-molecule medicines.